Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection

International Journal of Cancer

Volumn 101, Issue 2, 2002, Pages 151-155

  Friberg, Maria ^a   Jennings, Ronald ^a   Alsarraj, Marwan ^a   Dessureault, Sophie ^a   Cantor, Alan ^a   Extermann, Martine ^a   Mellor, Andrew L ^b   Munn, David H ^b   Antonia, Scott J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Indoleamine 2,3 dioxygenase; T cell; Tumor

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; N METHYLTRYPTOPHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; IMMUNE RESPONSE; LEWIS CARCINOMA; MONONUCLEAR CELL; MOUSE; MOUSE MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR ESCAPE;

ANIMALS; CELL DIVISION; FLOW CYTOMETRY; IMMUNE TOLERANCE; IMMUNOTHERAPY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON TYPE II; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; T-LYMPHOCYTES; TRYPTOPHAN; TRYPTOPHAN OXYGENASE; TUMOR CELLS, CULTURED;

EID: 0037056234     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10645     Document Type: Article

References (31)

1. The identification of cancer antigens: Impact on the development of cancer vaccines
2. Ex vivo staining of metastatic lymph nodes by Class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes
3. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice
4. Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo
5. Induction of antigen-specific T cell energy: An early event in the course of tumor progression
6. 4+ T cell- and IL-2-dependent mechanism
7. 4+ T cell tolerance to T cell priming through in vivo ligation of CD40
8. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions
9. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy
10. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes
11. Auto-aggression and tumor rejection: It takes more than self-specific T cell activation
12. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors
13. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy
14. Immune surveillance against a solid tumor fails because of immunological ignorance
15. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape
16. Human melanoma cells do not express Fas (Apo-I/CD95) ligand
17. Cutting edge: The tumor counterattack hypothesis revisited: Colon cancer cells Do not induce T cell apoptosis via the Fas (CD95, APO-l) pathway
18. Tryptophan catabolism and T-cell tolerance: Immunosuppression by starvation?
19. Inhibition of T cell proliferation by macrophage tryptophan catabolism
20. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation
21. Prevention of allogeneic fetal rejection by tryptophan catabolism
22. Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism
23. Induction of indoleamine 2,3-dioxygenase:a mechanism of the antitumor activity of interferon γ
24. Downregulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction
25. Establishment of a cloned line of Lewis Lung Carcinoma cells adapted to cell culture
26. Monoclonal antibodies against an H-2Kb-specific cytotoxic T cell clone detect several clone-specific molecules
27. Regulation of prostaglandin synthesis and cell adhesion by a tryptophan catabolizing enzyme
28. The host-tumor immune conflict: From immunosuppression to resistance and destruction
29. Tryptophan degradation in transplanted tumor cells undergoing rejection
30. IFN-γ is the inducer of indoleamine 2,3-dioxygenase in allografted tumor cells undergoing rejection
31. Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12